In 2012, the proportion of sales generated outside Europe grew to 58% (2011: 54%), largely driven by the strong sales growth in North America. Contributing to the 16.8% organic increase in sales were Rebif®, benefiting from year-on-year price increases, as well as the products from the Fertility and Endocrinology franchises. Sales in the Emerging Markets region developed favorably and grew 6.8% organically, based on the continued strong performance of the General Medicine franchise as well as Fertility products. Challenging business conditions in Europe, the division’s biggest geographic market, where pressures on health care budgets led to continuous price cuts across the industry, resulted in a 2.1% decline in organic sales. This was primarily due to lower sales of General Medicine products. Sales in the Rest of World region grew 12.0%, mainly thanks to the good performance of Glucophage® and Erbitux®.
Merck Serono | Sales by region – 2012
| XLS |
|
Merck Serono | Sales growth components by region – 2012 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ million / change in % |
Sales |
Organic |
Exchange |
Acquisitions/ divestments |
Reported |
|
Europe |
2,501.6 |
–2.1 |
0.4 |
– |
–1.7 |
|
North America |
1,334.8 |
16.8 |
8.8 |
– |
25.6 |
|
Emerging Markets |
1,737.1 |
6.8 |
2.2 |
– |
9.0 |
|
Rest of World |
422.3 |
12.0 |
4.7 |
– |
16.6 |
|
World in total |
5,995.8 |
4.9 |
2.8 |
– |
7.8 |
back
